Analysts’ Viewpoint on Hyperpigmentation Disorder Treatment Market Scenario
Increase in investment in R&D of novel advanced technologies, decrease in social taboo surrounding pigmentation, rise in prevalence of hyperpigmentation-related disorders, and surge in awareness about skin rejuvenation and treatment options are expected to drive the global hyperpigmentation disorder treatment market during the forecast period. Technological advancements in cosmeceuticals and the subsequent increase in usage of cosmeceuticals in skincare is providing lucrative opportunities for companies operating in the global market. Key players are increasingly investing in nanotechnology to introduce new and innovative products to increase their market share.
Pigmentation refers to areas of the skin that have darkened in color compared to the surrounding skin, often resulting in a patchy or uneven appearance. Pigmentation can appear as freckles and sunspots, melasma or chloasma, seborrheric keratosis, and birthmarks. It can be exacerbated by the usage of inappropriate skin care products as well as continued sun exposure and heat trauma. Hyperpigmentation occurs when melanocytes in the deeper layers of the skin produce melanin, a skin-darkening pigment. Melanin overproduction can result in darker skin patches on the skin's surface. Skin hypopigmentation is caused by a decrease in melanin production. Hyperpigmentation disorders can be treated with cosmeceuticals, laser treatment, and chemical peels. Furthermore, rise in prevalence of melasma and increase in awareness about hyperpigmentation treatment are driving the global hyperpigmentation disorders treatment market size.
Hyperpigmentation is quite common and relatively harmless. It could be a source of embarrassment for those who suffer from it. Hyperpigmentation, or a dark pigmentation patch on the face, causes an abnormally high concentration of skin pigments responsible for the production of melanocytes. Hyperpigmentation is most common in Mediterranean, Asian, African, and Latino populations.
Hyperpigmentation is a widespread and serious skin condition that affects people of all skin types. Despite the availability of various depigmentation active ingredients for skin hyperpigmentation disorders, none are completely satisfactory due to poor permeability through the skin layer and significant toxicity, resulting in severe side effects such as irritant dermatitis, erythema, itching, and skin flaking. Nanotechnology plays an important role in advancing cosmeceutical formulation by improving active ingredient solubility, stability, safety, loading efficiency, and dermal permeability.
Scientists have been investigating how nanotechnology can improve active ingredient delivery and absorption to the skin in addition to focusing on improving the efficacy of individual active agents. Nanotechnology has become a promising addition to the cosmetic industry due to its ability to improve the properties of cosmetic products in general. Nanotechnology has the potential to manipulate and improve features such as absorption, texture, active ingredient protection, and overall efficiency.
Depigmentation active ingredients such as hydroquinone, arbutin, kojic acid, azelaic acid, and retinoic acid; and new approaches in nanotechnology could improve the efficacy of hyperpigmentation treatments. Nanotechnology is a promising approach for topical hydroquinone administration to overcome hyperpigmentation with adequate skin penetration and low systemic absorption to reduce hydroquinone's adverse effects.
In terms of treatment type, the cosmeceuticals segment held significant market share in 2021. Cosmeceuticals are topical cosmetic-pharmaceutical blends that contain biologically active ingredients. They can enhance skin appearance. Cosmeceuticals are rapidly substituting conventional agents. Phytochemicals, or compounds derived from plants, are cosmeceuticals that have been shown to have a range of cellular effects for a number of dermatological diseases. Furthermore, cosmeceuticals are regularly used to treat hyperpigmentation. Hyperpigmentation disorders are generally difficult to treat, which necessitates the usage of skin lightening agents such as cosmeceuticals. These target hyperplastic melanocytes and inhibit key regulatory steps in melanin synthesis. Cosmeceuticals are the commonly preferred treatment measures in facial hyperpigmentation disorders due to high absorption and penetration in the skin.
Based on disease indication, the melasma segment accounted for the largest global hyperpigmentation disorder treatment market share in 2021. Melasma is a typically acquired condition of symmetric hyperpigmentation that usually affects the face. It is more common in women and people with darker skin types. Skin conditions such as melasma are quite prevalent, especially in pregnant women. Melasma affects 15% to 50% of pregnant mothers. Melasma can affect 1.5% to 33% of people, and it typically appears during a woman's reproductive years and infrequently during puberty. It typically begins between the age of 20 and 40. Rise in prevalence of melasma and increase in preference for cosmeceutical treatment have led to high demand for dermatological care. Melasma was significantly widespread in 2020, affecting more than 5 million people in the U.S. Asian women of childbearing age have melasma prevalence of up to 30%. It frequently recurs and is challenging to treat. The pathogenesis, clinical staging & classification, and clinical management of melasma have advanced significantly in the past few years. As per global hyperpigmentation disorders treatment market trends, rise in prevalence of melasma and increase in treatment options are expected to drive the segment in the next few years.
In terms of end-user, the esthetic clinics & dermatology centers segment is projected to account for major share of the global hyperpigmentation disorder treatment market during the forecast period. Increase in number of esthetic clinics & dermatological centers is expected to drive the segment in the near future. Manufacturers and retailers of hyperpigmentation cosmeceutical products are improving their supply chains to meet the growing demand for hyperpigmentation disorder treatment products. Other global players and retailers are encouraging several brands to adopt an omnichannel supply model for products to reach final customers.
Patients experience significant social and emotional stress due to hyperpigmentary disorders, particularly melasma and post-inflammatory hyperpigmentation (PIH). Despite the development of several treatment modalities for melasma and PIH, management of these conditions is difficult due to recurrent and refractory nature. Lasers have revolutionized the treatment of a number of dermatological conditions, particularly dermal or mixed melasma; pigmentary disorders are one of these. Lasers have been widely used to treat pigmented conditions such as Becker's nevus, cafe-au-lait macules, Nevus of Ota, nevocellular nevi, lentigines, tattoos, melasma, and post-inflammatory hyperpigmentation, with varying degrees of success.
Asia Pacific accounted for the largest share of around 35% of the global hyperpigmentation disorder treatment market in 2021. The market in the region is projected to be highly lucrative during the forecast period. Rise in adoption of laser treatment for several skin diseases, decrease in social taboos & increase in acceptance of pigmentation disorders treatment measures, surge in prevalence of numerous skin disorders, rise in awareness about skin rejuvenation, improvement in lifestyle, and increase in disposable income are expected to drive the market in the region.
Different geographic regions of the world, skin races, and age groups have different epidemiologies for pigmentary disorders. Around 6.9% of the patients in a Northern Indian study on childhood and adolescent dermatoses had pigmentary disorders. According to a study published in the International Journal of Molecular Sciences in 2018, dark-skinned people (South/Southeast Asian, Hispanic/Latin American, and African descent) have a higher prevalence of pigmentary disorders. These are also the third and fourth most common dermatoses in African Americans and Hispanics, respectively. Hence, the market in the region is expected to be driven by high prevalence of pigmentation disorders.
The global hyperpigmentation disorder treatment market is consolidated, with the presence of small number of leading players. Expansion of product portfolio and mergers & acquisitions are the key strategies adopted by the major players in the global hyperpigmentation disorder treatment market. Aerolase Corporation, Candela Corporation, Cynosure, Galderma S.A., iSCLINICAL, ISDIN, L'Oréal (SkinCeuticals, Skin betterscience & La Roche-Posay), LumenisBe Ltd., Mesoestetics, Obagi Cosmeceuticals LLC, PCA Skin, Scientis, Senté, and Skin Medica (AbbVie) are the prominent players operating in the global hyperpigmentation disorder treatment market and the hyperpigmentation treatment devices market.
Each of these players has been profiled in the hyperpigmentation disorder treatment market report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.
|
Attribute |
Detail |
|
Market Size Value in 2021 |
US$ 4.3 Bn |
|
Market Forecast Value in 2031 |
More than US$ 9.5 Bn |
|
Growth Rate (CAGR) |
8.5% |
|
Forecast Period |
2022–2031 |
|
Historical Data Available for |
2017–2020 |
|
Quantitative Units |
US$ Bn for Value |
|
Market Analysis |
It includes segment analysis as well as regional level analysis. Furthermore, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis. |
|
Competition Landscape |
|
|
Format |
Electronic (PDF) + Excel |
|
Market Segmentation |
|
|
Regions Covered |
|
|
Countries Covered |
|
|
Companies Profiled |
|
|
Customization Scope |
Available upon request |
|
Pricing |
Available upon request |
The global hyperpigmentation disorder treatment market was valued at US$ 4.3 Bn in 2021
The global hyperpigmentation disorder treatment market is projected to reach more than US$ 9.5 Bn by 2031
The global hyperpigmentation disorder treatment market is anticipated to grow at a CAGR of 8.5% from 2022 to 2031
Increase in incidence of melisma & post-inflammatory hyperpigmentation is driving the global hyperpigmentation disorders treatment market.
Asia Pacific is expected to account for major share of the global market during the forecast period.
Aerolase Corporation, Candela Corporation, Cynosure, Galderma S.A., iSCLINICAL, ISDIN, L'Oréal (SkinCeuticals, Skinbetterscience & La Roche-Posay), Lumenis Be Ltd., Mesoestetics, Obagi Cosmeceuticals LLC, PCA Skin, Scientis, Senté, and SkinMedica (AbbVie).
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Hyperpigmentation Disorder Treatment Market
4. Market Overview
4.1. Introduction
4.1.1. Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Hyperpigmentation Disorder Treatment Market Analysis and Forecast, 2017–2031
5. Key Insights
5.1. Key Market Trends
5.2. Merger and Acquisition
5.3. Strategies of Top Five Players Operating in the Market
5.4. Incidence of Orthopedic Disorder, by Key Countries
5.5. Regulatory and Reimbursement Scenario, by Key Countries
6. Global Hyperpigmentation Disorder Treatment Market Analysis and Forecast, by Treatment Type
6.1. Introduction & Definition
6.2. Market Value Forecast, by Treatment Type, 2017–2031
6.2.1. Cosmeceuticals
6.2.2. Laser Therapy
6.2.3. Chemical Peels
6.2.4. Microdermabrasion
6.2.5. Phototherapy
6.2.6. Others
6.3. Market Attractiveness, by Treatment Type
7. Global Hyperpigmentation Disorder Treatment Market Analysis and Forecast, by Disease Indication
7.1. Introduction & Definition
7.2. Market Value Forecast, by Disease Indication, 2017–2031
7.2.1. Melasma
7.2.2. Post-inflammatory Hyperpigmentation
7.2.3. Solar Lentigines
7.2.4. Others
7.3. Market Attractiveness Analysis, by Disease Indication
8. Global Hyperpigmentation Disorder Treatment Market Analysis and Forecast, by End-user
8.1. Introduction & Definition
8.2. Market Value Forecast, by End-user, 2017–2031
8.2.1. Hospitals
8.2.2. Esthetic Clinics & Dermatology Centers
8.2.3. Others
8.3. Market Attractiveness Analysis, by End-user
9. Global Hyperpigmentation Disorder Treatment Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. North America Hyperpigmentation Disorder Treatment Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Treatment Type, 2017–2031
10.2.1. Cosmeceuticals
10.2.2. Laser Therapy
10.2.3. Chemical Peels
10.2.4. Microdermabrasion
10.2.5. Phototherapy
10.2.6. Others
10.3. Market Value Forecast, by Disease Indication, 2017–2031
10.3.1. Melasma
10.3.2. Post-inflammatory Hyperpigmentation
10.3.3. Solar Lentigines
10.3.4. Others
10.4. Market Value Forecast, by End-user, 2017–2031
10.4.1. Hospitals
10.4.2. Esthetic Clinics & Dermatology Centers
10.4.3. Others
10.5. Market Value Forecast, by Country, 2017–2031
10.5.1. U.S.
10.5.2. Canada
10.6. Market Attractiveness Analysis
10.6.1. By Treatment Type
10.6.2. By Disease Indication
10.6.3. By End-user
10.6.4. By Country
11. Europe Hyperpigmentation Disorder Treatment Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Treatment Type, 2017–2031
11.2.1. Cosmeceuticals
11.2.2. Laser Therapy
11.2.3. Chemical Peels
11.2.4. Microdermabrasion
11.2.5. Phototherapy
11.2.6. Others
11.3. Market Value Forecast, by Disease Indication, 2017–2031
11.3.1. Melasma
11.3.2. Post-inflammatory Hyperpigmentation
11.3.3. Solar Lentigines
11.3.4. Others
11.4. Market Value Forecast, by End-user, 2017–2031
11.4.1. Hospitals
11.4.2. Esthetic Clinics & Dermatology Centers
11.4.3. Others
11.5. Market Value Forecast, by Country/Sub-region, 2017–2031
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Spain
11.5.5. Italy
11.5.6. Rest of Europe
11.6. Market Attractiveness Analysis
11.6.1. By Treatment Type
11.6.2. By Disease Indication
11.6.3. By End-user
11.6.4. By Country/Sub-region
12. Asia Pacific Hyperpigmentation Disorder Treatment Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Treatment Type, 2017–2031
12.2.1. Cosmeceuticals
12.2.2. Laser Therapy
12.2.3. Chemical Peels
12.2.4. Microdermabrasion
12.2.5. Phototherapy
12.2.6. Others
12.3. Market Value Forecast, by Disease Indication, 2017–2031
12.3.1. Melasma
12.3.2. Post-inflammatory Hyperpigmentation
12.3.3. Solar Lentigines
12.3.4. Others
12.4. Market Value Forecast, by End-user, 2017–2031
12.4.1. Hospitals
12.4.2. Esthetic Clinics & Dermatology Centers
12.4.3. Others
12.5. Market Value Forecast, by Country/Sub-region, 2017–2031
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Market Attractiveness Analysis
12.6.1. By Treatment Type
12.6.2. By Disease Indication
12.6.3. By End-user
12.6.4. By Country/Sub-region
13. Latin America Hyperpigmentation Disorder Treatment Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Treatment Type, 2017–2031
13.2.1. Cosmeceuticals
13.2.2. Laser Therapy
13.2.3. Chemical Peels
13.2.4. Microdermabrasion
13.2.5. Phototherapy
13.2.6. Others
13.3. Market Value Forecast, by Disease Indication, 2017–2031
13.3.1. Melasma
13.3.2. Post-inflammatory Hyperpigmentation
13.3.3. Solar Lentigines
13.3.4. Others
13.4. Market Value Forecast, by End-user, 2017–2031
13.4.1. Hospitals
13.4.2. Esthetic Clinics & Dermatology Centers
13.4.3. Others
13.5. Market Value Forecast, by Country/Sub-region, 2017–2031
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Market Attractiveness Analysis
13.6.1. By Treatment Type
13.6.2. By Disease Indication
13.6.3. By End-user
13.6.4. By Country/Sub-region
14. Middle East & Africa Hyperpigmentation Disorder Treatment Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Treatment Type, 2017–2031
14.2.1. Cosmeceuticals
14.2.2. Laser Therapy
14.2.3. Chemical Peels
14.2.4. Microdermabrasion
14.2.5. Phototherapy
14.2.6. Others
14.3. Market Value Forecast, by Disease Indication, 2017–2031
14.3.1. Melasma
14.3.2. Post-inflammatory Hyperpigmentation
14.3.3. Solar Lentigines
14.3.4. Others
14.4. Market Value Forecast, by End-user, 2017–2031
14.4.1. Hospitals
14.4.2. Esthetic Clinics & Dermatology Centers
14.4.3. Others
14.5. Market Value Forecast, by Country/Sub-region, 2017–2031
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Market Attractiveness Analysis
14.6.1. By Treatment Type
14.6.2. By Disease Indication
14.6.3. By End-user
14.6.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player - Competitive Matrix (by tier and size of companies)
15.2. Market Share Analysis, by Company (2021)
15.3. Company Profiles
15.3.1. Aerolase Corporation
15.3.1.1. Company Overview
15.3.1.2. Treatment Type Portfolio
15.3.1.3. SWOT Analysis
15.3.1.4. Financial Overview
15.3.1.5. Strategic Overview
15.3.2. Candela Corporation
15.3.2.1. Company Overview
15.3.2.2. Treatment Type Portfolio
15.3.2.3. SWOT Analysis
15.3.2.4. Financial Overview
15.3.2.5. Strategic Overview
15.3.3. Cynosure
15.3.3.1. Company Overview
15.3.3.2. Treatment Type Portfolio
15.3.3.3. SWOT Analysis
15.3.3.4. Financial Overview
15.3.4. Galderma S.A.
15.3.4.1. Company Overview
15.3.4.2. Treatment Type Portfolio
15.3.4.3. SWOT Analysis
15.3.4.4. Financial Overview
15.3.4.5. Strategic Overview
15.3.5. iSCLINICAL
15.3.5.1. Company Overview
15.3.5.2. Treatment Type Portfolio
15.3.5.3. SWOT Analysis
15.3.5.4. Financial Overview
15.3.5.5. Strategic Overview
15.3.6. ISDIN
15.3.6.1. Company Overview
15.3.6.2. Treatment Type Portfolio
15.3.6.3. SWOT Analysis
15.3.7. L'Oréal (SkinCeuticals, Skinbetterscience & La Roche-Posay)
15.3.7.1. Company Overview
15.3.7.2. Treatment Type Portfolio
15.3.7.3. SWOT Analysis
15.3.7.4. Strategic Overview
15.3.8. Lumenis Be Ltd.
15.3.8.1. Company Overview
15.3.8.2. Treatment Type Portfolio
15.3.8.3. SWOT Analysis
15.3.8.4. Strategic Overview
15.3.9. Mesoestetics
15.3.9.1. Company Overview
15.3.9.2. Treatment Type Portfolio
15.3.9.3. SWOT Analysis
15.3.9.4. Financial Overview
15.3.9.5. Strategic Overview
15.3.10. Obagi Cosmeceuticals LLC
15.3.10.1. Company Overview
15.3.10.2. Treatment Type Portfolio
15.3.10.3. SWOT Analysis
15.3.10.4. Financial Overview
15.3.10.5. Strategic Overview
15.3.11. PCA Skin
15.3.11.1. Company Overview
15.3.11.2. Treatment Type Portfolio
15.3.11.3. SWOT Analysis
15.3.11.4. Financial Overview
15.3.11.5. Strategic Overview
15.3.12. Scientis
15.3.12.1. Company Overview
15.3.12.2. Treatment Type Portfolio
15.3.12.3. SWOT Analysis
15.3.12.4. Financial Overview
15.3.12.5. Strategic Overview
15.3.13. Senté Labs
15.3.13.1. Company Overview
15.3.13.2. Treatment Type Portfolio
15.3.13.3. SWOT Analysis
15.3.13.4. Financial Overview
15.3.13.5. Strategic Overview
15.3.14. SkinMedica (AbbVie)
15.3.14.1. Company Overview
15.3.14.2. Treatment Type Portfolio
15.3.14.3. SWOT Analysis
15.3.14.4. Financial Overview
15.3.14.5. Strategic Overview
15.3.15. ZO Skin Health, Inc.
15.3.15.1. Company Overview
15.3.15.2. Treatment Type Portfolio
15.3.15.3. SWOT Analysis
15.3.15.4. Financial Overview
15.3.15.5. Strategic Overview
List of Tables
Table 01: Global Hyperpigmentation Disorder Treatment Market Size (US$ Mn) Forecast, by Treatment Type, 2017–2031
Table 02: Global Hyperpigmentation Disorder Treatment Market Size (US$ Mn) Forecast, by Disease Indication, 2017–2031
Table 03: Global Hyperpigmentation Disorder Treatment Market Size (US$ Mn) Forecast, by End-user, 2017–2031
Table 04: Global Hyperpigmentation Disorder Treatment Market Size (US$ Mn) Forecast, by Region, 2017–2031
Table 05: North America Hyperpigmentation Disorder Treatment Market Size (US$ Mn) Forecast, by Country, 2017–2031
Table 06: North America Hyperpigmentation Disorder Treatment Market Size (US$ Mn) Forecast, by Treatment Type, 2017–2031
Table 07: North America Hyperpigmentation Disorder Treatment Market Size (US$ Mn) Forecast, by Disease Indication, 2017–2031
Table 08: North America Hyperpigmentation Disorder Treatment Market Size (US$ Mn) Forecast, by End-user, 2017–2031
Table 09: Europe Hyperpigmentation Disorder Treatment Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 10: Europe Hyperpigmentation Disorder Treatment Market Size (US$ Mn) Forecast, by Treatment Type, 2017–2031
Table 11: Europe Hyperpigmentation Disorder Treatment Market Size (US$ Mn) Forecast, by Disease Indication, 2017–2031
Table 12: Europe Hyperpigmentation Disorder Treatment Market Size (US$ Mn) Forecast, by End-user, 2017–2031
Table 13: Asia Pacific Hyperpigmentation Disorder Treatment Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 14: Asia Pacific Hyperpigmentation Disorder Treatment Market Size (US$ Mn) Forecast, by Treatment Type, 2017–2031
Table 15: Asia Pacific Hyperpigmentation Disorder Treatment Market Size (US$ Mn) Forecast, by Disease Indication, 2017–2031
Table 16: Asia Pacific Hyperpigmentation Disorder Treatment Market Size (US$ Mn) Forecast, by End-user, 2017–2031
Table 17: Latin America Hyperpigmentation Disorder Treatment Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 18: Latin America Hyperpigmentation Disorder Treatment Market Size (US$ Mn) Forecast, by Treatment Type, 2017–2031
Table 19: Latin America Hyperpigmentation Disorder Treatment Market Size (US$ Mn) Forecast, by Disease Indication, 2017–2031
Table 20: Latin America Hyperpigmentation Disorder Treatment Market Size (US$ Mn) Forecast, by End-user, 2017–2031
Table 21: Middle East & Africa Hyperpigmentation Disorder Treatment Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 22: Middle East & Africa Hyperpigmentation Disorder Treatment Market Size (US$ Mn) Forecast, by Treatment Type, 2017–2031
Table 23: Middle East & Africa Hyperpigmentation Disorder Treatment Market Size (US$ Mn) Forecast, by Disease Indication, 2017–2031
Table 24: Middle East & Africa Hyperpigmentation Disorder Treatment Market Size (US$ Mn) Forecast, by End-user, 2017–2031
List of Figures
Figure 01: Global Hyperpigmentation Disorder Treatment Market Size (US$ Mn) and Distribution (%), by Region, 2018 and 2031
Figure 02: Global Hyperpigmentation Disorder Treatment Market Revenue (US$ Mn), by Treatment Type, 2021
Figure 03: Global Hyperpigmentation Disorder Treatment Market Value Share, by Treatment Type, 2021
Figure 04: Global Hyperpigmentation Disorder Treatment Market Value Share, by Disease Indication, 2021
Figure 05: Global Hyperpigmentation Disorder Treatment Market Value Share, by End-user, 2021
Figure 06: Global Hyperpigmentation Disorder Treatment Market Value Share, by Region, 2021
Figure 07: Global Hyperpigmentation Disorder Treatment Market Value (US$ Mn) Forecast, 2017–2031
Figure 08: Global Hyperpigmentation Disorder Treatment Market Value Share Analysis, by Treatment Type, 2017 and 2031
Figure 09: Global Hyperpigmentation Disorder Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Phototherapy, 2017–2031
Figure 10: Global Hyperpigmentation Disorder Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Cosmeceuticals, 2017–2031
Figure 11: Global Hyperpigmentation Disorder Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Chemical Peels, 2017–2031
Figure 12: Global Hyperpigmentation Disorder Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Microdermabrasion, 2017–2031
Figure 13: Global Hyperpigmentation Disorder Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Laser Therapy, 2017–2031
Figure 14: Global Hyperpigmentation Disorder Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2017–2031
Figure 15: Global Hyperpigmentation Disorder Treatment Market Attractiveness Analysis, by Treatment Type, 2022-2031
Figure 16: Global Hyperpigmentation Disorder Treatment Market Value Share Analysis, by Disease Indication, 2017 and 2031
Figure 17: Global Hyperpigmentation Disorder Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Melasma, 2017–2031
Figure 18: Global Hyperpigmentation Disorder Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Post-inflammatory Hyperpigmentation, 2017–2031
Figure 19: Global Hyperpigmentation Disorder Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Restorative Surgery, 2017–2031
Figure 20: Global Hyperpigmentation Disorder Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2017–2031
Figure 21: Global Hyperpigmentation Disorder Treatment Market Attractiveness Analysis, by Disease Indication, 2022-2031
Figure 22: Global Hyperpigmentation Disorder Treatment Market Value Share Analysis, by End-user, 2017 and 2031
Figure 23: Global Hyperpigmentation Disorder Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Hospitals, 2017–2031
Figure 24: Global Hyperpigmentation Disorder Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Esthetic Clinics & Dermatology Centers, 2017–2031
Figure 25: Global Hyperpigmentation Disorder Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2017–2031
Figure 26: Global Hyperpigmentation Disorder Treatment Market Attractiveness Analysis, by End-user, 2022-2031
Figure 27: Global Hyperpigmentation Disorder Treatment Market Value Share Analysis, by Region, 2017 and 2031
Figure 28: Global Hyperpigmentation Disorder Treatment Market Attractiveness Analysis, by Region, 2022-2031
Figure 29: North America Hyperpigmentation Disorder Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 30: North America Hyperpigmentation Disorder Treatment Market Attractiveness Analysis, by Country, 2017–2031
Figure 31: North America Hyperpigmentation Disorder Treatment Market Value Share Analysis, by Country, 2017 and 2031
Figure 32: North America Hyperpigmentation Disorder Treatment Market Value Share Analysis, by Treatment Type, 2017 and 2031
Figure 33: North America Hyperpigmentation Disorder Treatment Market Value Share Analysis, by Disease Indication, 2017 and 2031
Figure 34: North America Hyperpigmentation Disorder Treatment Market Value Share Analysis, by End-user, 2017 and 2031
Figure 35: North America Hyperpigmentation Disorder Treatment Market Attractiveness Analysis, by Treatment Type, 2022–2031
Figure 36: North America Hyperpigmentation Disorder Treatment Market Attractiveness Analysis, by Disease Indication, 2022–2031
Figure 37:North America Hyperpigmentation Disorder Treatment Market Attractiveness Analysis, by End-user, 2022–2031
Figure 38: Europe Hyperpigmentation Disorder Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 39: Europe Hyperpigmentation Disorder Treatment Market Attractiveness Analysis, by Country/Sub-region, 2017–2031
Figure 40: Europe Hyperpigmentation Disorder Treatment Market Value Share Analysis, by Country/Sub-region, 2017 and 2031
Figure 41: Europe Hyperpigmentation Disorder Treatment Market Value Share Analysis, by Treatment Type, 2017 and 2031
Figure 42: Europe Hyperpigmentation Disorder Treatment Market Value Share Analysis, by Disease Indication, 2017 and 2031
Figure 43: Europe Hyperpigmentation Disorder Treatment Market Value Share Analysis, by End-user, 2017 and 2031
Figure 44: Europe Hyperpigmentation Disorder Treatment Market Attractiveness Analysis, by Treatment Type, 2022–2031
Figure 45: Europe Hyperpigmentation Disorder Treatment Market Attractiveness Analysis, by Disease Indication, 2022–2031
Figure 46: Europe Hyperpigmentation Disorder Treatment Market Attractiveness Analysis, by End-user, 2022–2031
Figure 47: Asia Pacific Hyperpigmentation Disorder Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 48: Asia Pacific Hyperpigmentation Disorder Treatment Market Attractiveness Analysis, by Country/Sub-region, 2017–2031
Figure 49: Asia Pacific Hyperpigmentation Disorder Treatment Market Value Share Analysis, by Country/Sub-region, 2017 and 2031
Figure 50: Asia Pacific Hyperpigmentation Disorder Treatment Market Value Share Analysis, by Treatment Type, 2017 and 2031
Figure 51: Asia Pacific Hyperpigmentation Disorder Treatment Market Value Share Analysis, by Disease Indication, 2017 and 2031
Figure 52: Asia Pacific Hyperpigmentation Disorder Treatment Market Value Share Analysis, by End-user, 2017 and 2031
Figure 53: Asia Pacific Hyperpigmentation Disorder Treatment Market Attractiveness Analysis, by Treatment Type, 2022–2031
Figure 54: Asia Pacific Hyperpigmentation Disorder Treatment Market Attractiveness Analysis, by Disease Indication, 2022–2031
Figure 55: Asia Pacific Hyperpigmentation Disorder Treatment Market Attractiveness Analysis, by End-user, 2022–2031
Figure 56: Latin America Hyperpigmentation Disorder Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 57: Latin America Hyperpigmentation Disorder Treatment Market Attractiveness Analysis, by Country/Sub-region, 2017–2031
Figure 58: Latin America Hyperpigmentation Disorder Treatment Market Value Share Analysis, by Country/Sub-region, 2017 and 2031
Figure 59: Latin America Hyperpigmentation Disorder Treatment Market Value Share Analysis, by Treatment Type, 2017 and 2031
Figure 60: Latin America Hyperpigmentation Disorder Treatment Market Value Share Analysis, by Disease Indication, 2017 and 2031
Figure 61: Latin America Hyperpigmentation Disorder Treatment Market Value Share Analysis, by End-user, 2017 and 2031
Figure 62: Latin America Hyperpigmentation Disorder Treatment Market Attractiveness Analysis, by Treatment Type, 2022–2031
Figure 63: Latin America Hyperpigmentation Disorder Treatment Market Attractiveness Analysis, by Disease Indication, 2022–2031
Figure 64: Latin America Hyperpigmentation Disorder Treatment Market Attractiveness Analysis, by End-user, 2022–2031
Figure 65: Middle East & Africa Hyperpigmentation Disorder Treatment Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 66: Middle East & Africa Hyperpigmentation Disorder Treatment Market Attractiveness Analysis, by Country/Sub-region, 2017–2031
Figure 67: Middle East & Africa Hyperpigmentation Disorder Treatment Market Value Share Analysis, by Country/Sub-region, 2017 and 2031
Figure 68: Middle East & Africa Hyperpigmentation Disorder Treatment Market Value Share Analysis, by Treatment Type, 2017 and 2031
Figure 69: Middle East & Africa Hyperpigmentation Disorder Treatment Market Value Share Analysis, by Disease Indication, 2017 and 2031
Figure 70: Middle East & Africa Hyperpigmentation Disorder Treatment Market Value Share Analysis, by End-user, 2017 and 2031
Figure 71: Middle East & Africa Hyperpigmentation Disorder Treatment Market Attractiveness Analysis, by Treatment Type, 2022–2031
Figure 72: Middle East & Africa Hyperpigmentation Disorder Treatment Market Attractiveness Analysis, by Disease Indication, 2022–2031
Figure 73: Middle East & Africa Hyperpigmentation Disorder Treatment Market Attractiveness Analysis, by End-user, 2022–2031
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Hyperpigmentation Disorder Treatment Market
